已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study

医学 中止 不利影响 内科学 免疫抑制 前瞻性队列研究 队列研究 黑色素瘤 逻辑回归 外科 癌症研究
作者
Léo Plaçais,Stéphane Dalle,O. Dereure,Sabiha Trabelsi,S. Dalac,Délphine Legoupil,H. Montaudié,Jean‐Philippe Arnault,J. De Quatrebarbes,Philippe Saïag,F. Brunet‐Possenti,Thierry Lesimple,E. Maubec,F. Aubin,F. Granel‐Brocard,Jean‐Jacques Grob,Pierre‐Emmanuel Stoebner,Clara Allayous,Bastien Oriano,Caroline Dutriaux,Laurent Mortier,Célèste Lebbe
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:81 (10): 1445-1452 被引量:20
标识
DOI:10.1136/ard-2022-222186
摘要

To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma.Case-control study performed on a French multicentric prospective cohort of patients with melanoma, matched for irAE risk factors and oncological staging. Risk of irAE was assessed by logistic regression.110 patients with pAID were included and matched with 330 controls, from March 2013 to October 2020. Over a median follow-up period of 7.2 months for cases and 6.9 months for controls, the ORs of developing all-grade and grade ≥3 irAEs among cases compared with controls were 1.91 (95% CI (1.56 to 2.27)) and 1.44 (95% CI (1.08 to 1.82)), respectively. Patients with pAID had an increased risk of multiple irAEs (OR 1.46, 95% CI (1.15 to 2.67)) and a shorter time to irAE onset. In contrast, there were no difference in irAE-related mortality nor in the rate of treatment discontinuation, and a landmark analysis revealed a better survival at 24 months among cases (p=0.02). Thirty per cent of cases experienced a pAID flare during follow-up, and baseline immunosuppression did not prevent irAE occurrence. Last, we report associations between the pAID clinical subsets and organ-specific irAEs.In our study, patients with pAID were at greater risk of all-grade, severe and multiple irAEs, yet had a better 24-month survival than controls. Thus, patients with pAID should be eligible for ICI therapy but benefit from a close monitoring for irAE occurrence, especially during the first months of therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
等璃子发布了新的文献求助10
刚刚
1秒前
1秒前
哈哈发布了新的文献求助10
2秒前
vv发布了新的文献求助10
2秒前
4秒前
su完成签到 ,获得积分10
4秒前
隐形曼青的应助被Page_Page采纳,获得30
5秒前
科研狗完成签到,获得积分10
6秒前
七七完成签到,获得积分10
6秒前
6秒前
朱海兰发布了新的文献求助10
7秒前
8秒前
7766发布了新的文献求助30
8秒前
Owen的应助被科研通管家采纳,获得10
8秒前
8秒前
田様的应助被科研通管家采纳,获得10
8秒前
wheat的应助被科研通管家采纳,获得10
8秒前
小马甲的应助被科研通管家采纳,获得10
9秒前
微风发布了新的文献求助10
9秒前
科研狗发布了新的文献求助10
10秒前
怕黑凤妖完成签到 ,获得积分10
10秒前
Hase发布了新的文献求助30
11秒前
激情的冰绿完成签到 ,获得积分10
11秒前
小旋风完成签到,获得积分10
13秒前
13秒前
13秒前
15秒前
xc完成签到 ,获得积分10
16秒前
罗斌奇发布了新的文献求助20
16秒前
强健的寻云完成签到 ,获得积分10
17秒前
唯唯完成签到 ,获得积分10
19秒前
求求毕业发布了新的文献求助10
19秒前
李博文发布了新的文献求助10
20秒前
tiantianyuan完成签到 ,获得积分10
21秒前
坚定初阳完成签到 ,获得积分10
21秒前
h123完成签到,获得积分10
23秒前
25秒前
epmoct完成签到 ,获得积分0
25秒前
Gideon完成签到,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165423
求助须知:如何正确求助?哪些是违规求助? 9559005
关于积分的说明 21748579
捐赠科研通 7756086
什么是DOI,文献DOI怎么找? 3428919
关于科研通互助平台的介绍 2553193
邀请新用户注册赠送积分活动 2473473